Oncology Program Portfolio –
–Raised Series A funding for development of oncology program portfolio
Client approached with a pharma portfolio with a certain valuation in mind. Keeklee proposed to raise the round at a higher valuation by first a business development approach, followed by a raise. Key items undertaken for the project were
- Key opinion leaders for proper positioning of the programs, which improved the quality of the portfolio.
- Competitor Analysis in the field for similar programs and integration into the valuation models
- Options based term sheet for higher valuation
- Alternate revenue streams into the same program to increase the value of the IP
- Tie-up with R&D centers to conduct select experiments that bring value inflection
- Rewrite of the business plan
- Term sheet negotiation and closing the round a value higher than previously proposed by the company
–Lined up Series B / mezzanine financing and IPO (NASDAQ) opportunities